F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
12 nov. 2021 08h00 HE
|
F-star Therapeutics, Inc.
Dr. Michelle Morrow to present on F-star’s Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific Poster Presentation of Preclinical Data Demonstrates Potential for F-star’s...
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
11 nov. 2021 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
10 nov. 2021 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
10 nov. 2021 16h05 HE
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company...
CytoImmune Therapeutics Appoints Renowned Oncologist and Immunologist as New Chief Executive Officer
10 nov. 2021 08h00 HE
|
CytoImmune Therapeutics
LOS ANGELES, Nov. 10, 2021 (GLOBE NEWSWIRE) -- CytoImmune Therapeutics, a privately-held cell therapy company focused on developing natural killer (NK) immune cells to fight cancer, announces the...
PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
10 nov. 2021 07h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
08 nov. 2021 16h15 HE
|
Aprea Therapeutics
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
08 nov. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Fluidigm Announces Third Quarter 2021 Financial Results
08 nov. 2021 16h02 HE
|
Fluidigm Corporation
Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology...
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute
08 nov. 2021 08h30 HE
|
PDS Biotechnology Corporation
Advances Next Phase of Versamune® Oncology Pipeline FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company...